Original Source(s)
Related Content
FDA Approves Auvelity for Agitation in Alzheimer’s Disease
The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.
April 30, 2026
-
3 min
GLP-1 Drugs Tied to Lower Addiction Risk
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
May 27, 2026
-
5 min
FDA Monthly Preview: Key May Decisions to Watch
Several FDA decisions across multiple specialties are expected this month.
April 29, 2026
-
4 min